Paragon 28 to Showcase Innovations and Leadership at the 43rd Annual J.P. Morgan Healthcare Conference
ENGLEWOOD, Colo. Paragon 28, Inc. (NYSE: FNA), a prominent figure in the medical device sector focusing solely on foot and ankle orthopedic solutions, is set to present at the illustrious 43rd Annual J.P. Morgan Healthcare Conference. The event will take place on Monday, January 13, 2025, at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time. Spearheading the presentation at the conference will be Albert DaCosta, Chairman and CEO, alongside Chadi Chahine, CFO & EVP of Supply Chain Operations. This opportunity reflects the company s commitment to innovation and leadership in the niche field of orthopedic devices for foot and ankle treatments.
Paragon 28 s participation in this high-profile conference comes on the heels of several exciting developments within the company. One of the major highlights is the introduction of the SMART28 Case Management Portal. This revolutionary platform represents the forefront of Paragon 28 s SMART28 initiative, aimed at transforming foot and ankle treatments through advanced technology. The portal employs artificial intelligence to streamline the coordination of patient-specific surgical plans, offering a seamless user experience to healthcare professionals. The first case utilizing the SMART Bun-Yo-Matic, a part of the SMART28 ecosystem, marks a significant milestone for the company. This ecosystem encompasses a suite of solutions and products designed to enhance various aspects of orthopedic care, reaffirming Paragon 28 s dedication to pioneering advancements in healthcare technology.
Another critical update from Paragon 28 includes significant changes in its leadership team and financial strategies. Effective August 5, 2024, Chadi Chahine was appointed as the Chief Financial Officer and Executive Vice-President of Supply Chain Operations. Chahine s appointment represents a strategic move to bolster the company s operational efficiency and financial oversight as it continues to navigate the complexities of the healthcare market.
Furthermore, Paragon 28 has released its financial results for the second quarter of 2024, concluding on June 30. Along with the announcement of these results, the company has adjusted its 2024 net revenue guidance, reflecting a nuanced outlook on its market performance. This adjustment is indicative of Paragon 28 s proactive approach in managing financial expectations and maintaining transparency with its stakeholders.
As Paragon 28 prepares to present at the J.P. Morgan Healthcare Conference, these developments underscore its trajectory of growth and innovation. The combination of cutting-edge technology, strategic leadership appointments, and precise financial management positions the company as a formidable player in the orthopedic device market.
For those interested in witnessing Paragon 28 s presentation, a live webcast along with an archived recording will be accessible on the company s website. This opportunity allows stakeholders and interested parties to glean insights into Paragon 28 s strategic vision and future initiatives.
Comments